Heparin has been used extensively as an antithrombotic and anticoagulant for close to 100
years. This anticoagulant activity is attributed mainly to the pentasaccharide sequence …

Background The primary manifestation of coronavirus disease 2019 (COVID‐19) is
respiratory insufficiency that can also be related to diffuse pulmonary microthrombosis and …

Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …

Abstract The coronavirus disease 2019 (COVID-19) is a highly transmissible disease
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that poses a …

Background: The efficacy and safety of prophylactic full-dose anticoagulation and
antiplatelet therapy in critically ill COVID-19 patients remain uncertain. Methods: COVID …

Clinical, laboratory, and autopsy findings support an association between coronavirus
disease-2019 (COVID-19) and thromboembolic disease. Acute COVID-19 infection is …

Background Patients hospitalized with COVID-19 often exhibit markers of a hypercoagulable
state and have an increased incidence of VTE. In response, CHEST issued rapid clinical …

Thromboembolism is a common and deadly consequence of COVID-19 infection for
hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and …

Infection with the SARS-CoV-2 virus, resulting in COVID-19 disease, has presented a
unique scenario associated with high rates of thrombosis. The risk of venous thrombosis is …

Background The clinical impact of different prophylactic anticoagulation regimens among
hospitalized patients with coronavirus disease 2019 (COVID-19) remains unclear. We …